Kojima, Yoshitsugu
Yamada, Sakiko
Kamijima, Kunitoshi
Kogushi, Kentaro
Ikeda, Shunya
Funding for this research was provided by:
Otsuka Pharmaceutical
Article History
Received: 2 April 2024
Accepted: 2 August 2024
First Online: 2 September 2024
Declarations
:
: The 2016 and 2018 Japan NHWS survey were approved with exemption status upon review by Pearl Institutional Review Board (Indianapolis, IN, IRB Study Number: 16-KAN-124 and 18-KANT-162). All NHWS respondents provided informed online consent prior to participating.
: Not applicable.
: YK and SY are employees of Otsuka Pharmaceutical Co., Ltd., Japan. KKAMIJIMA has received speakers’ or consultant honoraria from Otsuka Pharmaceutical Co., Ltd., Sumitomo Pharma Co., Ltd., and Viatris Pharmaceuticals Japan, Inc. SI declares no competing interests. KKOGUSHI was an ex-employee of Otsuka Pharmaceutical Co., Ltd., Japan and is an employee of AbbVie GK.